Pepex Biomedical
Earth City · Founded 2001
About Pepex Biomedical
Pepex® Biomedical is a medical device and health care technology company building the industry’s first big data platform dedicated to diabetes. Think Flatiron for Cancer. Pepex has developed the next generation of enzymatic-based biosensors with 246 Patents worldwide. The advanced sensor designs provide methods for measuring metabolic analytes at the cellular level for improved patient care and diagnostics. We have utilized this Patented Sensor Platform Technology and built the first Blood Glucose Meter (BGM) with wireless connectivity to the Cloud. The mTrio BGM and sensor cartridge is ready for manufacturing. mTrio and Pepex Health Cloud will allow Healthcare Providers to enhance the quality of Clinical Care, Improve Patient Outcomes & Satisfaction, and Lower Provider Costs related to Diabetes. 1) Empower Providers (insurance companies) to better manage their Diabetes Population Health 2) Empower Physicians to quickly diagnose and decide on real-time interventions to improve patient outcomes 3) Empower Patients (Diabetics) with proactive home healthcare and self monitoring tools 4) Empower Life Sciences to develop an accurate understanding of the real-world of diabetes care, support & advance clinical therapies and enhance research and drug development efforts We are seeking a total of $4.4MM to execute our Go To Market Strategy and close out this round with a Strategic Investor or Partner. Use of Funds; (A) Manufacture mTrio BGM and build the Sensor Cartridge Machines (B) Build the Big Data Cloud Platform and Software
Company Facts
- Founded: 2001
- Legal name: Pepex Biomedical, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $22.2M
- Funding stage: Private Equity
- Last round: Private Equity (Jul 2015)
- Website: pepex.com
- Phone: (240)506-3170
Social Profiles
Canonical: https://fsome.com/organization/pepex-biomedical-8271529 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.